Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Integrase strand transfer inhibitor (INSTI) antiretroviral

Dolutegravir

TIVICAY

Dosage form
Tablet
Available strengths
5 mg (dispersible tablet), 10 mg, 25 mg, 50 mg
Drug class
Integrase strand transfer inhibitor (INSTI) antiretroviral
Common brand
TIVICAY

Clinical overview. Dolutegravir (brand name TIVICAY) is an HIV integrase strand transfer inhibitor taken by mouth, in combination with other antiretroviral medicines, to treat HIV-1 infection in adults and children 4 weeks of age and older who meet weight requirements. It can be taken with or without food, though certain antacids, calcium and iron supplements, and several other medications can reduce its effectiveness if taken too close together. Rare but serious risks include liver toxicity and hypersensitivity reactions, and consistent daily use is essential to help prevent the virus from developing resistance.

Indication

Common therapeutic uses

  • Dolutegravir, combined with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults.
  • It is also indicated for integrase-inhibitor-naïve pediatric patients aged 4 weeks and older weighing at least 3 kg, in combination with other antiretrovirals.
  • Alternative combinations that avoid metabolic-inducing drugs should be used where possible in patients with confirmed or suspected resistance to integrase inhibitors.

Pregnancy

Risk assessment and monitoring considerations

  • Dolutegravir should not be used during pregnancy unless the potential benefit outweighs the potential risk to the fetus.
  • Large birth-outcome surveillance studies involving tens of thousands of pregnancies have not shown a significant difference in the rate of neural tube defects among infants born to people taking dolutegravir at conception compared with other antiretroviral regimens or with HIV-negative pregnancies.
  • An earlier interim analysis from one of these surveillance studies had raised a potential signal for neural tube defects with dolutegravir exposure around conception; later, larger analyses did not confirm a significantly increased risk.
  • Dolutegravir readily crosses the placenta, and umbilical cord blood concentrations in newborns are slightly higher than the mother's own blood concentrations.
  • Animal reproduction studies did not show teratogenicity or significant fetal harm at doses many times the human exposure.
  • Healthcare professionals are encouraged to register pregnant patients exposed to dolutegravir with the Antiretroviral Pregnancy Registry.

Breastfeeding

Infant exposure considerations

  • Mothers with HIV should not breastfeed their infants, to avoid the risk of passing HIV through breast milk.
  • Dolutegravir passes into human breast milk in small amounts.
  • Nursing mothers taking dolutegravir should be instructed not to breastfeed.

Geriatrics

Dosing and tolerability considerations

  • Clinical studies did not include enough patients aged 65 and older to determine whether they respond differently than younger adults.
  • Caution should be used when dosing older adults, given the greater likelihood of reduced liver, kidney, or heart function, and of other health conditions or medications.

Pediatrics

Use in children and adolescents

  • Dolutegravir is approved for integrase-inhibitor-naïve pediatric patients aged 4 weeks and older weighing at least 3 kg, dosed according to body weight.
  • It has not been established as safe and effective in infants under 4 weeks of age, infants weighing less than 3 kg, or children with documented or suspected resistance to integrase inhibitors.
  • Dispersible tablets are recommended for children weighing less than 20 kg, or for any patient who cannot swallow tablets whole; to reduce choking risk, no more than one tablet should be swallowed at a time.

Dosage & Administration

Practical dosing and administration

  • The usual adult dose is 50 mg once daily for treatment-naïve or integrase-inhibitor-naïve treatment-experienced patients; patients with confirmed integrase-inhibitor resistance take 50 mg twice daily.
  • The dose is increased to 50 mg twice daily when dolutegravir is combined with certain enzyme-inducing drugs, such as efavirenz, rifampin, tipranavir/ritonavir, or fosamprenavir/ritonavir.
  • Pediatric dosing is weight-based, ranging from 5 mg once daily in infants weighing 3 to less than 6 kg up to the standard 50 mg adult dose in children weighing 20 kg or more, using either the dispersible or regular tablet.
  • Dispersible tablets may be swallowed whole with water or dispersed in water and taken within 30 minutes of dispersing; they must not be chewed, cut, or crushed, and are not interchangeable milligram-for-milligram with regular tablets.
  • No dose adjustment is required for mild or moderate liver impairment; dolutegravir is not recommended in severe liver impairment because it has not been studied in this population.
  • No dose adjustment is required for mild, moderate, or severe kidney impairment in patients without integrase-inhibitor resistance; caution is needed in resistant patients with severe kidney impairment, since lower drug levels may allow further resistance to develop.
  • If a dose is missed, it should be taken as soon as possible unless it is within 4 hours of the next scheduled dose, in which case the missed dose should be skipped; doses should never be doubled.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is limited experience with dolutegravir overdose; doses up to 250 mg in healthy subjects produced no symptoms beyond those seen at recommended doses.
  • There is no specific treatment or antidote; management is supportive.
  • Dolutegravir is highly bound to plasma proteins, so it is unlikely to be significantly removed by dialysis.

Common side effects

Frequently reported tolerability concerns

  • Insomnia may occur.
  • Headache may occur.
  • Fatigue may occur.
  • Nausea may occur.
  • Diarrhea may occur.
  • Abnormal or vivid dreams may occur.
  • Dizziness may occur.
  • Skin rash may occur.
  • Vertigo may occur.
  • Abdominal pain, abdominal discomfort, gas, or vomiting may occur.
  • Joint or muscle pain may occur.
  • Weight gain has been reported.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Liver toxicity, including elevated liver enzymes, hepatitis, and acute liver failure, has been reported, even in patients with no pre-existing liver disease.
  • Severe hypersensitivity reactions have occurred, marked by rash together with fever, fatigue, muscle or joint aches, blisters, mouth sores, swelling of the face, or liver inflammation; dolutegravir must be stopped immediately if this occurs.
  • Immune reconstitution inflammatory syndrome, an inflammatory reaction to hidden infections or autoimmune conditions as the immune system recovers, can occur, sometimes months after starting treatment.
  • Worsening of liver enzyme levels can occur in patients with hepatitis B or C co-infection, particularly if anti-hepatitis B treatment is stopped or interrupted.
  • Reversible sideroblastic anemia, a blood disorder affecting red blood cell formation, has been reported.
  • Acute liver failure has been reported after marketing.
  • Suicidal thoughts or suicide attempts have been reported, particularly in patients with a prior history of depression or mental illness.
  • Depression has been reported.
  • Kidney impairment has been reported.
  • Seek urgent medical attention for yellowing of the skin or eyes, a severe rash with fever, or thoughts of self-harm.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with hepatitis B or C co-infection, and monitor liver chemistry closely, especially at the start of therapy.
  • Use with caution in patients with any degree of liver impairment; dolutegravir is not recommended in severe liver impairment.
  • Exercise caution when driving or operating machinery, since dizziness can occur.
  • Use with caution in patients switching between tablet and dispersible tablet formulations, since they are not interchangeable milligram-for-milligram and incorrect dosing can lead to underdosing or greater side effects.
  • Use with caution in older adults due to a higher likelihood of reduced organ function or other medical conditions.
  • Monitor serum creatinine, as dolutegravir can cause a modest increase by blocking its tubular secretion without truly reducing kidney filtration function.
  • Patients on antiretroviral therapy, including dolutegravir, can still develop opportunistic infections and should remain under regular medical observation.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to dolutegravir or to any ingredient in the formulation.
  • Contraindicated in combination with dofetilide, due to the risk of life-threatening dofetilide toxicity.
  • Contraindicated in combination with fampridine (also known as dalfampridine), due to an increased risk of seizures.

Drug interactions

Clinically relevant combinations

  • Etravirine reduces dolutegravir levels; the dolutegravir dose must be increased to twice daily unless etravirine is combined with a boosted protease inhibitor.
  • Efavirenz and rifampin reduce dolutegravir levels and require an increase to twice-daily dolutegravir dosing.
  • Nevirapine co-administration should be avoided due to insufficient data to guide dosing.
  • Anticonvulsants including oxcarbazepine, phenytoin, phenobarbital, and carbamazepine reduce dolutegravir levels and require twice-daily dosing.
  • Antacids and other products containing polyvalent cations such as magnesium or aluminum, laxatives, sucralfate, and buffered medications significantly reduce dolutegravir absorption; dolutegravir should be taken 2 hours before or 6 hours after these products.
  • Calcium and iron supplements, including multivitamins containing them, can be taken at the same time as dolutegravir if taken with food; under fasting conditions, dolutegravir should be taken 2 hours before or 6 hours after these supplements.
  • Dolutegravir increases metformin levels, so a metformin dose adjustment may be needed when starting or stopping dolutegravir.
  • St. John's Wort can lower dolutegravir levels and should generally be avoided, or the dolutegravir dose increased to twice daily if it is used.
  • Atazanavir and atazanavir/ritonavir increase dolutegravir levels, but no dose adjustment is needed.
  • Tipranavir/ritonavir and fosamprenavir/ritonavir reduce dolutegravir levels and require twice-daily dosing.
  • No clinically relevant interaction was found with midazolam, tenofovir, methadone, rilpivirine, daclatasvir, or hormonal contraceptives containing norgestimate and ethinyl estradiol.

Food interactions

Meal-related administration

  • Dolutegravir tablets and dispersible tablets may be taken with or without food; food increases the amount absorbed but is not required for the medication to work.

Time of administration

Practical scheduling

  • Dolutegravir is usually taken once daily (or twice daily if required by interacting medications) at a consistent time, with or without food; when combined with calcium or iron supplements under fasting conditions, it should be spaced 2 hours before or 6 hours after those supplements.

Storage

Product handling

  • Store TIVICAY 5 mg dispersible tablets and 10 mg tablets in the original container to protect from moisture, with the bottle tightly closed and the desiccant left in place; store below 25°C.
  • Store TIVICAY 25 mg and 50 mg tablets below 30°C.

Patient take-away

Key counselling points for a quick closing summary

  • Dolutegravir (TIVICAY) is an antiretroviral medication taken with other HIV medicines to control HIV-1 infection.
  • It can be taken with or without food, and the dispersible tablet form should not be chewed, cut, or crushed.
  • Report any signs of liver problems, such as yellowing skin or eyes, or a severe rash with fever, right away.
  • Keep dolutegravir spaced away from antacids, calcium or iron supplements, and certain other medications, as directed by your pharmacist.
  • Continue taking dolutegravir exactly as prescribed, even if you feel well, since missing doses can lead to drug resistance.

References

Source material and product information

  1. Health Canada Product Monograph — Dolutegravir

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.